UCB has agreed to acquire Ra Pharmaceuticals (Ra Pharma), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases of the complement system. With the deal, UCB gains access to zilucoplan, a Phase III peptide inhibitor of C5 for the treatment of generalised myasthenia gravis which will complement its own Phase III candidate for this disease, rozanolixizumab, which targets the neonatal Fc receptor instead. The deal comes as UCB looks for late-stage assets to mitigate the upcoming loss of exclusivities of its products Neupro® (rotigotine), Vimpat® (lacosamide) and Cimzia® (certolizumab pegol).